EP-4739327-A1 - BIFIDOBACTERIUM ANIMALIS SUBSP LACTIS STRAIN CECT 8145 AND LTA THEREOF HEALTH USES

Abstract

The invention relates to health uses of a composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145, in the form of viable and non-viable cells. and/or a lipoteichoic acid (LT A) thereof, more particularly, for its use in anxiety, pathogen protection, gut barrier or age-related conditions in a subject. Given the associated effects, the invention is thus useful for exploitation in pharmaceutical and veterinary areas, food and beverages developments, animal feed, or medical foods among others.

Inventors

• MARTORELL GUEROLA, PATRICIA
• RAMÓN VIDAL, Daniel
• Chenoll Cuadros, Maria Empar
• TORTAJADA SERRA, MARTA
• ÁLVAREZ PÉREZ, Beatriz
• BALAGUER VIDAL, Ferrán
• BARRENA CASTILLO, Marta
• ENRIQUE LÓPEZ, María
• MAICAS IRIGARAY, Miren

Assignees

• Biopolis, S.L.

Dates

Publication Date

20260513

Application Date

20240704

Claims (20)

1. 1. Composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145 and/or a lipoteichoic acid (LTA) thereof, for use in the treatment and/or prevention of anxiety disorders in a subject.
2. 2. Composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145 and/or a lipoteichoic acid (LTA) thereof, for use in the treatment and/or prevention of a pathogen infection in a subject, preferably wherein the pathogen is a bacterium.
3. 3. Composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145 and/or a lipoteichoic acid (LTA) thereof, for use in restoring the integrity of gut barrier in a subject.
4. 4. Composition for use according to any one of claims 1 to 3, wherein the Bifidobacterium animalis subsp. lactis strain is in the form of viable cells.
5. 5. Composition for use according to any one of claims 1 to 3, wherein the Bifidobacterium animalis subsp. lactis strain is in the form of non-viable cells, preferably wherein the non-viable cells are heat-treated.
6. 6. Composition for use according to any one of claims 1 to 5, wherein the strain is present in an amount between 10 5 cfu and 10 12 cfu per gram or milliliter of the composition.
7. 7. Composition for use according to any one of claims 1 to 6, wherein the composition is formulated for administration in liquid form or in solid form.
8. 8. Composition for use according to claim 7, wherein the solid formulation is selected from the group consisting of tablets, lozenges, sweets, chewable tablets, chewing gum, capsules, sachets, powders, granules, coated particles or coated tablets, tablets and gastro-resistant tablets and capsules and dispersible strips and/or films.
9. 9. Composition for use according to claim 7, wherein the liquid formulation is selected from the group consisting of oral solutions, suspensions, droplets, emulsions and syrups.
10. 10. Composition for use according to any one of claims 1 to 9, wherein the composition is a pharmaceutical composition or a nutritional composition.
11. 11. Composition for use according to claim 10, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and/or an excipient.
12. 12. Composition for use according to claim 10, wherein the nutritional composition is a food or a nutritional supplement.
13. 13. Composition for use according to claim 12, wherein the food is selected from the group consisting of fruit or vegetable juices, ice cream, infant formula, milk, yogurt, cheese, fermented milk, milk powder, cereals, baked goods, milk-based products, meat products and beverages.
14. 14. Non-therapeutic use of a composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145, and/or a lipoteichoic acid (LTA) thereof, in the reduction of anxiety and/or an anxiety-related condition in a subject.
15. 15. Non-therapeutic use according to claim 14, wherein the anxiety related condition is selected from the list consisting of anxiousness, stress, worry, nervousness and unease.
16. 16. Non-therapeutic use of a composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145, and/or a lipoteichoic acid (LTA) thereof, in alleviating unpleasant effects and/or discomfort associated to the presence of a pathogen in a subject.
17. 17. Non-therapeutic use according to claim 16, wherein the pathogen is a bacterium belonging to Salmonella or Staphylococcus genus.
18. 18. Non-therapeutic use of a composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145, and/or a lipoteichoic acid (LTA) thereof, for improving the gut barrier function or maintaining the gut barrier integrity in a subject.
19. 19. Use of a composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145, and/or a lipoteichoic acid (LTA) thereof, for improving age-related conditions, and/or increasing lifespan and/or promoting longevity in a subject.
20. 20. LTA obtained by cultivating Bifidobacterium animalis subsp. lactis strain CECT 8145 in excess of sugars as carbon source, wherein the LTA has the capacity to reduce and/or reverse stress and/or anxiety in a subject.

Description

Bifidobacterium animalis subsp lactis strain CECT 8145 and LTA thereof health uses The present invention falls within the food, feed and pharmaceutical industries. In particular, the invention relates to health uses of a composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145, in the form of viable and non-viable cells, and/or a lipoteichoic acid (LTA) thereof, more particularly, for its use in anxiety, pathogen protection, gut barrier or age-related conditions in a subject. BACKGROUND ART Life expectancy has increased globally by more than 6 years in the period from 2000 to 2019 while healthy life expectancy without disabilities has not improved at the same level (following WHO guidelines). In recent years, the role of human gut microbiota has been highlighted as key to maintain healthy aging and gut dysbiosis can contribute to the initiation and/or progress of many diseases (Coman, V. & Vodnar, D. C. Gut microbiota and old age: Modulating factors and interventions for healthy longevity. Exp Gerontol 141 , 111095, doi:10.1016/j.exger.2020.111095 (2020)). In this context, discovering and understanding the mechanisms of action of nutraceuticals as probiotics and postbiotics that promote healthy aging is key to delay age-related pathologies. It has been previously shown the effectiveness of the Bifidobacterium animalis subsp. lactis strain CECT 8145 (BPL1), its heat-treated form (HT-BPL1) and a novel postbiotic, the lipoteichoic acid (LTA), on fat reduction using the animal model Caenorhabditis elegans (C. elegans), as disclosed in Martorell, P. et al. Probiotic Strain Bifidobacterium animalis subsp. lactis CECT 8145 Reduces Fat Content and Modulates Lipid Metabolism and Antioxidant Response in Caenorhabditis elegans. J Agric Food Chem 64, 3462-3472, doi:10.1021/acs.jafc.5b05934 (2016). LTA was one of the first key probiotic effector molecules reported in modulation of obesity (Balaguer, F. etal. Lipoteichoic acid from Bifidobacterium animalis subsp. lactis BPL1 : a novel postbiotic that reduces fat deposition via IGF-1 pathway. Microb Biotechnol, doi:10.1111/1751-7915.13769 (2021). On the other hand, some other strains belonging to Bifidobacterium animalis subsp. lactis are known to exert health beneficial effects, as well as in the improvement of particular conditions. For instance, in Dong W, et al., Front Psychol. 2021 Jan 13; 11 :570298, it is disclosed a study related to the effects produced by the intake of Bifidobacterium animalis subsp. lactis Bb-12 in athletes anxiety state and sports performance under stress. Given the ever-increasing ageing of the population, there is a need in the field for finding alternative strains and compositions with positive health effects, as well as for the improvement of particular conditions, for instance in anxiety disorders, pathogen protection, intestinal integrity or age-related disorders. DESCRIPTION OF THE INVENTION The authors of the present invention have demonstrated new functionalities and beneficial health effects exerted by Bifidobacterium animalis subsp. lactis strain CECT 8145 (also known in the Example section as BPL1), including heat-treated cells (HT- BPL1), and its lipoteichoic acid (LT A). In particular, inventors of the present invention have shown that viable and heat- treated cells of Bifidobacterium animalis subsp. lactis strain CECT 8145, as well as its LTA, (i) improve anxiety and stress related behaviors (as shown in Examples, in particular in section 2.2), (ii) exert ability to protect against pathogen (as shown in Examples, section 2.5), (iii) promote gut barrier integrity (as shown in Examples, section 2.6), and (iv) promote longevity effects having a positive impact in lifespan and age-related conditions, as shown, for instance in the lifespan assays (Examples, section 2.7), C. elegans Alzheimer’s model (section 2.2. in Examples) or in further examples of BPL1 , HT-BPL1 and LTA-BPL1 effects in aging and longevity (Examples, section 4). Furthermore, comparative assays were performed in C.elegans models, showing that Bifidobacterium animalis subsp. lactis strain CECT 8145 has a better effect on anxiety/stress-related behaviors than other strains belonging to Bifidobacterium animalis or Bifidobacterium longum (Examples, sections 2.3 and 2.4, and section 5). Likewise, comparative assays in nematodes’ longevity were also carried out, showing that supplementation with Bifidobacterium animalis subsp. lactis strain CECT 8145 exerts a higher effect on C. elegans lifespan than other strains belonging to Bifidobacterium animalis (Examples, section 2.8) or Bifidobacterium longum (Examples, section 4.4). Similarly, protection of Bifidobacterium animalis subsp. lactis strain CECT 8145 on pathogen infection in C. elegans was compared with other alternative Bifidobacterium animalis strains, showing that nematodes fed with Bifidobacterium animalis subsp. lactis strain CECT 8145 exhibited significant higher worms’ survival than th